361.28
-37.01 (-9.29%)
| Previous Close | 398.29 |
| Open | 399.40 |
| Volume | 1,523,115 |
| Avg. Volume (3M) | 1,293,967 |
| Market Cap | 47,730,077,696 |
| Price / Earnings (TTM) | 1,129.00 |
| Price / Earnings (Forward) | 55.87 |
| Price / Sales | 16.49 |
| Price / Book | 224.97 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -11.49% |
| Operating Margin (TTM) | 3.04% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | 20.20% |
| Total Debt/Equity (MRQ) | 2,358.25% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | -45.11 M |
| Levered Free Cash Flow (TTM) | 223.09 M |
| Return on Assets (TTM) | -1.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alnylam Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 2.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 3.81% |
| % Held by Institutions | 97.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 549.00 (Jefferies, 51.96%) | Buy |
| Median | 527.00 (45.87%) | |
| Low | 351.00 (Leerink Partners, -2.85%) | Hold |
| Average | 499.00 (38.12%) | |
| Total | 7 Buy, 2 Hold | |
| Avg. Price @ Call | 417.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 12 Jan 2026 | 529.00 (46.42%) | Buy | 370.91 |
| Needham | 12 Jan 2026 | 529.00 (46.42%) | Buy | 370.91 |
| Truist Securities | 08 Jan 2026 | 530.00 (46.70%) | Buy | 399.40 |
| Leerink Partners | 15 Dec 2025 | 351.00 (-2.85%) | Hold | 391.50 |
| Stifel | 11 Dec 2025 | 508.00 (40.61%) | Buy | 412.63 |
| Wells Fargo | 11 Nov 2025 | 479.00 (32.58%) | Hold | 451.95 |
| Barclays | 31 Oct 2025 | 527.00 (45.87%) | Buy | 456.04 |
| Piper Sandler | 31 Oct 2025 | 489.00 (35.35%) | Buy | 456.04 |
| Jefferies | 30 Oct 2025 | 549.00 (51.96%) | Buy | 449.56 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FITZGERALD KEVIN JOSEPH | 398.29 | 370.44 | 0 | 106,220 |
| GARG PUSHKAL | 398.29 | 370.91 | 2,290 | 953,428 |
| GREENSTREET YVONNE | 398.29 | 370.91 | 9,426 | 4,016,500 |
| POULTON JEFFREY V. | 398.29 | 370.91 | 3,413 | 1,435,480 |
| TANGULER TOLGA | 398.29 | 370.91 | 2,290 | 953,428 |
| Aggregate Net Quantity | 17,419 | |||
| Aggregate Net Value ($) | 7,465,055 | |||
| Aggregate Avg. Buy ($) | 398.29 | |||
| Aggregate Avg. Sell ($) | 370.75 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FITZGERALD KEVIN JOSEPH | Officer | 13 Jan 2026 | Automatic sell (-) | 2,290 | 369.96 | 847,208 |
| FITZGERALD KEVIN JOSEPH | Officer | 12 Jan 2026 | Sell (-) | 1,510 | 370.91 | 560,074 |
| TANGULER TOLGA | Officer | 12 Jan 2026 | Sell (-) | 1,510 | 370.91 | 560,074 |
| POULTON JEFFREY V. | Officer | 12 Jan 2026 | Sell (-) | 2,780 | 370.91 | 1,031,130 |
| GREENSTREET YVONNE | Officer | 12 Jan 2026 | Sell (-) | 9,577 | 370.91 | 3,552,205 |
| GARG PUSHKAL | Officer | 12 Jan 2026 | Sell (-) | 1,510 | 370.91 | 560,074 |
| FITZGERALD KEVIN JOSEPH | Officer | 11 Jan 2026 | Acquired (+) | 3,800 | 398.29 | 1,513,502 |
| TANGULER TOLGA | Officer | 11 Jan 2026 | Acquired (+) | 3,800 | 398.29 | 1,513,502 |
| POULTON JEFFREY V. | Officer | 11 Jan 2026 | Acquired (+) | 6,193 | 398.29 | 2,466,610 |
| GREENSTREET YVONNE | Officer | 11 Jan 2026 | Acquired (+) | 19,003 | 398.29 | 7,568,705 |
| GARG PUSHKAL | Officer | 11 Jan 2026 | Acquired (+) | 3,800 | 398.29 | 1,513,502 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |